Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04201457 · ClinicalTrials.gov registry record · Phase 1
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
A Phase 1 study of Low Grade Glioma (LGG) of Brain With BRAF Aberration and High Grade Glioma (HGG) of the Brain With BRAF Aberration, sponsored by Pediatric Brain Tumor Consortium.
- Active
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 15
- Study locations
NCT04201457 is a Phase 1 study of Low Grade Glioma (LGG) of Brain With BRAF Aberration and High Grade Glioma (HGG) of the Brain With BRAF Aberration that is active but no longer recruiting, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 57 participants. The trial reports 15 study locations across 13 states.
The verdict
NCT04201457, a Phase 1 study of Low Grade Glioma (LGG) of Brain With BRAF Aberration and High Grade Glioma (HGG) of the Brain With BRAF Aberration, is active but no longer recruiting, sponsored by Pediatric Brain Tumor Consortium.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 15
- Study locations
Study Summary
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.
Conditions Studied
Interventions
- DRUG Trametinib
- DRUG Dabrafenib
- DRUG Hydroxychloroquine
Study Locations (15)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children's Hospital at Stanford University Medical Center - Palo Alto
Ohio
- Cincinnati Children Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Arizona
- Phoenix Children's Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- University of Florida - Gainesville
Georgia
- Children's Healthcare of Atlanta - Atlanta
Illinois
- Lurie Children's Hospital-Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2020-01-17 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04201457
The ClinicalTrials.gov registry entry for NCT04201457 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Low Grade Glioma (LGG) of Brain With BRAF Aberration appearing as the primary indexed condition, and to 3 interventions - of which Trametinib is the first listed.
NCT04201457 reports 15 study locations spanning 13 distinct geographic areas - top geographies include California, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT04201457 about?
NCT04201457 is a clinical study titled "A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration". This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that ca...
What is the current status of trial NCT04201457?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2020-01-17. Estimated completion is 2026-03-31.
What conditions does trial NCT04201457 study?
This clinical trial studies the following conditions: Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1.
What interventions are being tested in trial NCT04201457?
The interventions under investigation include: Trametinib (DRUG), Dabrafenib (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04201457?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04201457 being conducted?
This trial has 15 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Low Grade Glioma (LGG) of Brain With BRAF Aberration
All registered trials for this condition
High Grade Glioma (HGG) of the Brain With BRAF Aberration
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.